Skip to main content
. 2021 Oct 25;11:757919. doi: 10.3389/fonc.2021.757919

Figure 6.

Figure 6

The immune landscape and immune checkpoint profiles of TAMIS. (A). Relationships between TAMIS and immune cell infiltrations in TCGA-CHOL. (B) SubMap analysis manifested that the low-risk group could be more sensitive to the anti-PD-1 therapy (Bonferroni P =0.047). (C) Distribution difference of TIDE and TIS prediction score between the high-risk and low-risk groups. (D). Correlations between TAMIS and PD-1, PD-L1, CTLA-4, CD40, HHLA2, TGFB1, and CMTM6 in TCGA-CHOL. (E) Distribution difference of PD-L1 and CMTM6 expression between the high-risk and low-risk groups. (F–H) Correlations between TAMIS and CD8A, PD-L1, and CMTM6 in our cohort. (I) Representative IHC staining images of CD8A, PD-L1, and CMTM6 between two risk groups. (J) Analysis of IHC scores between two risk groups according to the staining results of CD8A, PD-L1, and CMTM6. *P < 0.05, **P < 0.01, ****P < 0.0001.